BOSTON, Jan. 08, 2026 -- Aktis Oncology, Inc. (“Aktis”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed...

FlowCardia launches peripheral CROSSER catheters in the US
FlowCardia, Inc., a medical device company developing a portfolio of endovascular devices for the treatment of coronary and peripheral chronic total occlusions (CTOs), announced FDA 510(k) clearance and immediate U.S. launch of the CROSSER 14P, CROSSER 14S and CROSSER 18 CTO Recanalization Catheters.